Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reforms in Pharma on Snail Pace (India)

This article was originally published in PharmAsia News

Executive Summary

India-based pharmaceutical companies are calling on government officials to reform the country's price control policy. They claim the government does not take into account the costs of packaging when establishing price restrictions on drugs. Drug manufacturers say without this consideration, it is not cost effective to produce packaging necessary to discourage the sale of substandard imitation drugs. This leaves pharmaceutical companies with a major dilemma. They can either foot the cost of packaging or risk a glut of fraudulent drugs flooding the market. Representatives for India's pharmaceutical companies worry that to avoid this quandary some manufacturers will stop making price controlled products. Unfortunately, the 75 drugs on India's price controlled list, like Iron and Vitamin A supplements, are necessary for the health of the country's population. (Click here for more

You may also be interested in...



Bayer's Finerenone Hints Positive In Diabetic Kidney Disease

The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

UsernamePublicRestriction

Register

RS150180

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel